Lead Product(s): DNL758
Therapeutic Area: Infections and Infectious Diseases Product Name: SAR443122
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Denali Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Dosing of DNL758 has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.